Germany, France, Italy and Spain halt use of AstraZeneca vaccine - Al Jazeera English | Canada News Media
Connect with us

Business

Germany, France, Italy and Spain halt use of AstraZeneca vaccine – Al Jazeera English

Published

 on


Germany, France, Italy and Spain have suspended the use of AstraZeneca’s COVID-19 vaccine after several reports of blood clots in people who received the shot in Europe.

The flurry of suspensions on Monday came after a number of other countries, mostly in Europe, halted their rollouts late last week.

The World Health Organization (WHO) has backed the use of the vaccine and said it has seen no evidence that the shot had caused clotting.

The UN health agency is reviewing the reports related to shot and urged countries not to suspend vaccinations, as its top scientist said people should not panic.

The European Medicines Agency (EMA) said in a statement that it has not found any evidence of links between reported thrombosis cases and the AstraZeneca shot, saying that the shot’s benefits outweigh the risks and was safe to use. The regulator is reviewing the shot and will issue a decision on any further action on Thursday, it said.

EU members halt shots

German Health Minister Jens Spahn said the country suspended the use of the shot on the advice of the national vaccine regulator, the Paul Ehrlich Institute.

The institute had called for further investigation into seven reported cases of clots in the brains of people who had received this vaccination.

“Today’s decision is a purely precautionary measure,” Spahn said.

France and Italy announced similar moves shortly afterwards.

French President Emmanuel Macron said the use of the AstraZeneca shot would be suspended as a precautionary measure until at least Tuesday afternoon when the European Union’s medicines regulator – the EMA – will issue its recommendation over the vaccine.

Macron did not elaborate on the reasoning behind the decision, but told a news conference he hoped France would be able to vaccinate with AstraZeneca shots again “soon”.

Italy’s medicines authority AIFA meanwhile said it was implementing its own suspension as a “precautionary and temporary measure” pending rulings by the EMA.

The announcement followed the seizure of hundreds of thousands of doses of the vaccine by Italian prosecutors in the northern region of Piedmont, where a teacher died following his vaccination.

Experts are investigating whether there is a connection between his death and the vaccination.

Late on Monday, Spain’s Health Minister Carolina Darias said the country was suspending its use of the vaccine for two weeks as a “precaution”.

She said the decision would remain in place until the EMA “analyses the recent incidences of blood clots, notably over the weekend”.

AstraZeneca has said there is no cause for concern with its vaccine, which is jointly produced with the United Kingdom’s University of Oxford, and that there were fewer reported thrombosis cases in those who received the shot than in the general population.

Peter Drobac of Oxford University told Al Jazeera the AstraZeneca vaccine went through “rigorous clinical trials” and blood clots were not identified as a problem.

“The safety pause, I think it is certainly the prerogative of the regulators in these countries. However we have heard from the World Health Organization, the European Medicines Agency and others, that at this point the benefits of vaccination clearly outweigh the risks,” Drobac said.

WHO urges calm

The EMA and the WHO also said available data does not suggest the vaccine caused the clots and people should continue to be immunised with the shot.

The WHO on Monday called on countries not to suspend vaccinations against a disease that has caused more than 2.7 million deaths worldwide. The UN health agency’s top scientist reiterated that there have been no documented deaths linked to COVID-19 vaccines.

“We do not want people to panic,” Soumya Swaminathan said, adding there has been no association, so far, pinpointed between so-called “thromboembolic events” reported in some countries and COVID-19 shots.

The reassurances appear to have done little to calm doubts, however, with several countries having now temporarily halted the use of the AstraZeneca vaccine in recent days.

Denmark, Norway, Ireland, the Netherlands, Iceland, Bulgaria, Portugal and Slovenia were among those to suspend the use of the shot.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version